These data suggest that strategies targeting ELK1 inhibition, such as TDE, which specifically interferes with DEF docking domain of ELK1 to inhibit its phosphorylation and nuclear translocation44, may enhance learning and memory capabilities, potentially offering therapeutic benefits for cognitive disorders such as AD. The gene discussed is ELK1; the disease is Alzheimer disease.